Contributors: Department of Nephrology and Hypertension Erlangen, Germany; Friedrich-Alexander Universität Erlangen-Nürnberg = University of Erlangen-Nuremberg (FAU); Department of Biostatistics and Epidemiology Philadelphia; Perelman School of Medicine; University of Pennsylvania-University of Pennsylvania; Division of Pediatric Nephrology Philadelphia, USA; Children’s Hospital of Philadelphia (CHOP ); Centre for Chronic Disease Queensland, Australia; The University of Queensland (UQ All campuses : Brisbane, Dutton Park Gatton, Herston, St Lucia and other locations ); Department of Nephrology Nagoya, Japan; Nagoya University Graduate School of Medicine Japon; Nephrology and Hypertension Innsbruck, Austria; Innsbruck Medical University = Medizinische Universität Innsbruck (IMU); School of Clinical Sciences Bristol, U.K.; University of Bristol Bristol; Division of Pediatric Nephrology; Universität Heidelberg Heidelberg = Heidelberg University; Institute of Public Health Berlin, Germany; Charité - UniversitätsMedizin = Charité - University Hospital Berlin; Directora Division Epidemiologia Montevideo, Uruguay; Ministerio de Salud Publica; Centre de recherche en épidémiologie et santé des populations (CESP); Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM); Division of Nephrology Würzburg, Germany; Julius-Maximilians-Universität Würzburg (JMU); Renal Division Beijing, China; Peking University Beijing; Division of Nephrology Vancouver, BC, Canada; University of British Columbia (UBC); Department of Medicine Philadelphia, USA
نبذة مختصرة : International audience ; AbstractBackgroundChronic kidney disease (CKD) is a global health burden, yet it is still underrepresented within public health agendas in many countries. Studies focusing on the natural history of CKD are challenging to design and conduct, because of the long time-course of disease progression, a wide variation in etiologies, and a large amount of clinical variability among individuals with CKD. With the difference in health-related behaviors, healthcare delivery, genetics, and environmental exposures, this variability is greater across countries than within one locale and may not be captured effectively in a single study.MethodsStudies were invited to join the network. Prerequisites for membership included: 1) observational designs with a priori hypotheses and defined study objectives, patient-level information, prospective data acquisition and collection of bio-samples, all focused on predialysis CKD patients; 2) target sample sizes of 1,000 patients for adult cohorts and 300 for pediatric cohorts; and 3) minimum follow-up of three years. Participating studies were surveyed regarding design, data, and biosample resources.ResultsTwelve prospective cohort studies and two registries covering 21 countries were included. Participants age ranges from >2 to >70 years at inclusion, CKD severity ranges from stage 2 to stage 5. Patient data and biosamples (not available in the registry studies) are measured yearly or biennially. Many studies included multiple ethnicities; cohort size ranges from 400 to more than 13,000 participants. Studies’ areas of emphasis all include but are not limited to renal outcomes, such as progression to ESRD and death.ConclusionsiNET-CKD (International Network of CKD cohort studies) was established, to promote collaborative research, foster exchange of expertise, and create opportunities for research training. Participating studies have many commonalities that will facilitate comparative research; however, we also observed substantial differences. The ...
Processing Request
No Comments.